Pharmacy Medical Necessity Guidelines:
Droxidopa Capsules

Effective: March 10, 2026

Prior Authorization Required	√	Type of Review – Care Management	
Not Covered		Type of Review – Clinical Review	√
Pharmacy (RX) or Medical (MED) Benefit	RX	Department to Review	RXUM
These pharmacy medical necessity guidelines apply to the following: ☒ Tufts Health RITogether – A Rhode Island Medicaid Plan		**Fax Numbers:** RXUM: 617.673.0939	

Note: This guideline does not apply to Medicare Members (includes dual eligible Members).

OVERVIEW

FDA APPROVED INDICATIONS

Northera (droxidopa) is FDA-approved for the treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.

Effectiveness of droxidopa beyond two weeks of treatment has not been demonstrated. The continued effectiveness of droxidopa should be assessed periodically.

COVERAGE GUIDELINES

The plan may authorize coverage of **droxidopa capsules** for Members, when the following criteria are met:

1. Documented diagnosis of symptomatic neurogenic orthostatic hypotension

AND

2. Documentation the Member has had an inadequate response, adverse reaction, or contraindication to both midodrine and fludrocortisone

LIMITATIONS

1. Requests for brand-name products, which have AB-rated generics, will be reviewed according to Brand Name criteria.

CODES

None

REFERENCES

1. Freeman R. Neurogenic orthostatic hypotension. N Engl J Med. 2008; 358(6):615-24.
2. Freeman R, Wieling W, Axelrod FB et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21:69–72.
3. Isaacson S, Hauser RA, Szakacs CB et al. Droxidopa treatment on orthostatic symptoms and standing systolic blood pressure in patients with Parkinson's disease and symptomatic neurogenic orthostatic hypotension: study 306. Poster presented at the 65th annual meeting of the American Academy of Neurology. San Diego, CA; 2013 March 16-23. Poster 010.
4. Isaacson SH, Skettini J. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa. Vasc Health Risk Manag. 2014;10:169-76.
5. Kaufmann H, Malamut R, Norcliffe-Kaufmann L et al. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res. 2012; 22(2):79-90.
6. Kaufmann H, Freeman R, Biaggioni et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. In press.
7. Lanier JB, Mote MB, Clay EC. Evaluation and management of orthostatic hypotension. Am Fam Physician. 2011; 84(5):527-536.
8. Low PA. Prevalance of orthostatic hypotension. Clin Auton Res. 2008; 18(Suppl 1):8-13.
9. Metzler M, Duerr S, Granata R et al. Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. J Neurol. 2013; 260(9):2212-9.
10. prescribing information. Morgantown, WV: Mylan Pharmaceuticals Inc.; 2017 February.
11. National Institute for Health and Care Excellence (NICE). URL: nice.org.uk/. Available from Internet. Accessed 2014 July 3.

12. Northera prescribing information. Deerfield, IL: Lundbeck NA Ltd.; July 2019.
13. Parsaik AK, Singh B, Altayar O et al. Midodrine for orthostatic hypotension: a systematic review and meta-analysis of clinical trials. J Gen Intern Med. 2013; 28(11):1496-503.
14. Pharmaceutical Benefit Scheme. URL: pbs.gov.au/pbs/home. Available from Internet. Accessed 2014 July 3.
15. Shibao C, Lipsitz LA, Biaggioni I. ASH position paper: evaluation and treatment of orthostatic hypotension. J Clin Hypertens (Greenwich). 2013;15(3):147-53.

APPROVAL HISTORY

September 13, 2022: Reviewed by Pharmacy & Therapeutics Committee.

Subsequent endorsement date(s) and changes made:

1. June 13, 2023: No changes.
2. March 12, 2024: Effective April 1, 2024, updated fax number for RxUM.
3. March 11, 2025: No changes
4. March 10, 2026: No changes.

BACKGROUND, PRODUCT AND DISCLAIMER INFORMATION

Pharmacy Medical Necessity Guidelines have been developed for determining coverage for plan benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. The plan makes coverage decisions on a case-by-case basis considering the individual member's health care needs. Pharmacy Medical Necessity Guidelines are developed for selected therapeutic classes or drugs found to be safe, but proven to be effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in the service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. The plan revises and updates Pharmacy Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

For self-insured plans, coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a Pharmacy Medical Necessity Guideline and a self-insured Member's benefit document, the provisions of the benefit document will govern.

Treating providers are solely responsible for the medical advice and treatment of members. The use of this policy is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization and utilization management guidelines when applicable, and adherence to plan policies and procedures and claims editing logic.

Provider Services